The applicaton discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

An indole derivative as expressed by Formula (I), a preparation method thereof, a pharmaceutical salt, and use thereof as a therapeutic agent, especially as a FGFR inhibitor. Each substituent in Formula (I) has identical definition as specified in the specification.

##STR00001##

An indole derivative as expressed by Formula (I), a preparation method thereof, a pharmaceutical salt, and use thereof as a therapeutic agent, especially as a FGFR inhibitor. Each substituent in Formula (I) has identical definition as specified in the specification.

##STR00001##

A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R.sup.7-R.sup.9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q.sup.1 and Q.sup.2 independently represents a single bond or the like; each of A.sup.1 and A.sup.2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R.sup.1-R.sup.6 independently represents a hydrogen atom or the like.)

##STR00001##

A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R.sup.7-R.sup.9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q.sup.1 and Q.sup.2 independently represents a single bond or the like; each of A.sup.1 and A.sup.2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R.sup.1-R.sup.6 independently represents a hydrogen atom or the like.)

##STR00001##

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an -adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.